Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8238 results

  1. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Kidney Cancer Quality Standard

    In development Reference number: GID-QS10186 Expected publication date:  19 March 2026

    Quality standard
    In development

  4. Statement of intent on NICE's approach to ongoing evaluations ahead of proposed changes to NICE's standard cost-effectiveness thresholds: nice general consultation

    We are listening to your views on this NICE general. Comments close 30 January 2026.

    NICE guideline
    In consultation

  5. Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]

    Awaiting development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  8. Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Luspatercept for treating anaemia caused by myelofibrosis [TSID12309]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Rare diseases

    In development Reference number: GID-QS10197 Expected publication date:  27 February 2026

    Quality standard
    In development

  11. DB-OTO for Hearing loss [TSID12321]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Domestic Abuse: draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 27 January 2026.

    NICE guideline
    In consultation

  13. Tirzepatide for managing overweight and obesity in people 12 to 17 years [TSID12322]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation